LYT-200
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for LYT-200, covering 2025-02-12 to 2025-05-28. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) [Phase 1]